Appointments

Pierce named vice president of clinical development

Published in Gene Therapy Weekly, December 26th, 2002

Avigen, Inc., (AVGN) announced that Glenn Pierce, PhD, MD, has joined the company as vice president, clinical development responsible for all of Avigen's gene therapy clinical trials.

Avigen's lead product, Coagulin-B for the treatment of hemophilia B is currently in a phase I/II clinical trial, and the company expects to file an Investigation New Drug Application and enter the clinic with a treatment for Parkinson disease next year.

Pierce is an internationally recognized expert in gene therapy with 20 years experience in designing and managing preclinical research, clinical trials and academic collaborations in hemophilia, neurobiology, and tissue...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-12-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry